Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Receptors, Peptide”

199 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 199 results

Early research (Phase 1)Looking for participantsNCT07007117
What this trial is testing

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Who this might be right for
Refractory NeuroblastomaRelapsed NeuroblastomaHigh-Risk Neuroblastoma
Stephan Grupp MD PhD 38
Large-scale testing (Phase 3)WithdrawnNCT01860742
What this trial is testing

Randomized Phase III of PRRT Versus Interferon

Who this might be right for
Gastro-intestinal Neuroendocrine Tumors
Jules Bordet Institute
Not applicableNot Yet RecruitingNCT07538791
What this trial is testing

Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)

Who this might be right for
PheochromocytomasParagangliomas
Azienda USL Reggio Emilia - IRCCS 210
Early research (Phase 1)Looking for participantsNCT05870423
What this trial is testing

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors

Who this might be right for
Neuroendocrine TumorsPeptide Receptor Radionuclide Therapy
Erasmus Medical Center 24
Testing effectiveness (Phase 2)Active Not RecruitingNCT02754297
What this trial is testing

Personalized PRRT of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorCarcinoma, Neuroendocrine
CHU de Quebec-Universite Laval 275
Testing effectiveness (Phase 2)Ended earlyNCT04023331
What this trial is testing

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

Who this might be right for
NeuroblastomaRelapsed NeuroblastomaRefractory Neuroblastoma
Clarity Pharmaceuticals Ltd 21
Not applicableUnknownNCT05268627
What this trial is testing

Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss

Who this might be right for
Obesity
Mansoura University 38
Early research (Phase 1)UnknownNCT06081322
What this trial is testing

Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors

Who this might be right for
Advanced Pancreatic Cancer and Cholangiocarcinoma
Zhejiang University 29
Not applicableStudy completedNCT05427032
What this trial is testing

HRQoL During PRRT in Patients With NETs

Who this might be right for
Neuroendocrine TumorsQuality of LifePeptide Receptor Radionuclide Therapy
Uppsala University 756
Testing effectiveness (Phase 2)Study completedNCT02230176
What this trial is testing

Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II

Who this might be right for
Pancreatic Neuroendocrine Carcinoma
Gustave Roussy, Cancer Campus, Grand Paris 84
Early research (Phase 1)Study completedNCT01315847
What this trial is testing

Positron Emission Tomography (PET) Study of Brain Calcitonin Gene-Related Peptide (CGRP) Receptor Occupancy After Telcagepant Administration (MK-0974-067)

Who this might be right for
Migraine
Merck Sharp & Dohme LLC 10
Testing effectiveness (Phase 2)Study completedNCT04385992
What this trial is testing

Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET

Who this might be right for
Neuroendocrine Tumors
IRCCS San Raffaele 31
Very early researchLooking for participantsNCT05011760
What this trial is testing

[C-11]NPA PET-amphetamine in Cocaine Use Disorders

Who this might be right for
Cocaine Use Disorder
Rajesh Narendran 30
Testing effectiveness (Phase 2)Looking for participantsNCT07541209
What this trial is testing

Safety and Efficacy of PTH-IA

Who this might be right for
Jansen's Metaphyseal Chondrodysplasia
National Institute of Dental and Craniofacial Research (NIDCR) 12
Early research (Phase 1)Active Not RecruitingNCT06379217
What this trial is testing

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Who this might be right for
Metastatic Neuroendocrine Prostate Cancer
Novartis Pharmaceuticals 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT03012100
What this trial is testing

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Bilateral Breast CarcinomaBreast Inflammatory CarcinomaStage IB Breast Cancer AJCC v7+9 more
Academic and Community Cancer Research United 280
Testing effectiveness (Phase 2)Looking for participantsNCT07523633
What this trial is testing

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

Who this might be right for
Cannabis Use DisorderCannabis Use DisordersCannabis Abuse+2 more
Anders Fink-Jensen, MD, DMSci 100
Testing effectiveness (Phase 2)Ended earlyNCT00706992
What this trial is testing

Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients

Who this might be right for
Melanoma
National Cancer Institute (NCI) 50
Testing effectiveness (Phase 2)Looking for participantsNCT06247995
What this trial is testing

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 58
Not applicableLooking for participantsNCT07027995
What this trial is testing

Food and Fitness With Medicine (FFWM)

Who this might be right for
Cardiovascular Kidney Metabolic SyndromeType 2 Diabetes
Ohio State University 200
Load More Results